These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 11251013)

  • 21. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer.
    Carey MS; Bacon M; Tu D; Butler L; Bezjak A; Stuart GC
    Gynecol Oncol; 2008 Jan; 108(1):100-5. PubMed ID: 17920108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Symptom clusters of ovarian cancer patients undergoing chemotherapy, and their emotional status and quality of life.
    Hwang KH; Cho OH; Yoo YS
    Eur J Oncol Nurs; 2016 Apr; 21():215-22. PubMed ID: 26645947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes and patient-based hearing status in conductive hearing loss.
    Stewart MG
    Laryngoscope; 2001 Nov; 111(11 Pt 2 Suppl 98):1-21. PubMed ID: 11802001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument.
    Ward WL; Hahn EA; Mo F; Hernandez L; Tulsky DS; Cella D
    Qual Life Res; 1999 May; 8(3):181-95. PubMed ID: 10472150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reliability and validity of the body image after breast cancer questionnaire.
    Baxter NN; Goodwin PJ; McLeod RS; Dion R; Devins G; Bombardier C
    Breast J; 2006; 12(3):221-32. PubMed ID: 16684320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
    Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; Perrone F; ; ; ; ;
    Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Performance Status Scale for Head and Neck Cancer Patients and the Functional Assessment of Cancer Therapy-Head and Neck Scale. A study of utility and validity.
    List MA; D'Antonio LL; Cella DF; Siston A; Mumby P; Haraf D; Vokes E
    Cancer; 1996 Jun; 77(11):2294-301. PubMed ID: 8635098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quality of life assessment during adjuvant and salvage chemotherapy for advance stage epithelial ovarian cancer.
    Le T; Hopkins L; Kee Fung MF
    Gynecol Oncol; 2005 Jul; 98(1):39-44. PubMed ID: 15907986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer.
    Doyle C; Crump M; Pintilie M; Oza AM
    J Clin Oncol; 2001 Mar; 19(5):1266-74. PubMed ID: 11230467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Depression, anxiety, and quality of life in patients with epithelial ovarian cancer.
    Bodurka-Bevers D; Basen-Engquist K; Carmack CL; Fitzgerald MA; Wolf JK; de Moor C; Gershenson DM
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):302-8. PubMed ID: 10985884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validity of the Japanese version of functional assessment of cancer therapy-gastric (FACT-Ga) and its sensitivity to ascites volume change: a retrospective analysis of Japanese clinical trial participants.
    Maeda H; Sato M; Kobayashi M; Takiguchi N; Yoshikawa T; Yoshino S; Yoshida K; Tsuburaya A; Sakamoto J; Morita S
    Support Care Cancer; 2016 Nov; 24(11):4515-21. PubMed ID: 27272031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality of life issues in the management of ovarian cancer.
    Fish LS; Lewis BE
    Semin Oncol; 1999 Feb; 26(1 Suppl 1):32-9. PubMed ID: 10071971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a cancer-specific anterior skull base quality-of-life questionnaire.
    Gil Z; Abergel A; Spektor S; Shabtai E; Khafif A; Fliss DM
    J Neurosurg; 2004 May; 100(5):813-9. PubMed ID: 15137599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study.
    Wenzel LB; Huang HQ; Armstrong DK; Walker JL; Cella D;
    J Clin Oncol; 2007 Feb; 25(4):437-43. PubMed ID: 17264340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health-related quality of life outcomes of docetaxel/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: results from a randomized clinical trial.
    Pokrzywinski R; Secord AA; Havrilesky LJ; Puls LE; Holloway RW; Lewandowski GS; Higgins RV; Nycum LR; Kohler MF; Revicki DA
    Gynecol Oncol; 2011 Dec; 123(3):505-10. PubMed ID: 21945310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reliability and validity of the Functional Living Index-Cancer in Turkish cancer patients.
    Bektas HA; Akdemir N
    Cancer Nurs; 2008; 31(1):E1-7. PubMed ID: 18176121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality of life assessments in epithelial ovarian cancer patients during and after chemotherapy.
    Le T; Hopkins L; Fung Kee Fung M
    Int J Gynecol Cancer; 2005; 15(5):811-6. PubMed ID: 16174229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology group study.
    Almadrones L; McGuire DB; Walczak JR; Florio CM; Tian C
    Oncol Nurs Forum; 2004 May; 31(3):615-23. PubMed ID: 15146227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and validation of the functional assessment of cancer therapy-antiangiogenesis subscale.
    Kaiser K; Beaumont JL; Webster K; Yount SE; Wagner LI; Kuzel TM; Cella D
    Cancer Med; 2015 May; 4(5):690-8. PubMed ID: 25619758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Longitudinal assessment of quality of life and lifestyle in newly diagnosed ovarian cancer patients: the roles of surgery and chemotherapy.
    von Gruenigen VE; Frasure HE; Jenison EL; Hopkins MP; Gil KM
    Gynecol Oncol; 2006 Oct; 103(1):120-6. PubMed ID: 16556458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.